Redmile Group LLC Has $2.51 Million Stake in Repare Therapeutics Inc. (NASDAQ:RPTX)

Redmile Group LLC lowered its holdings in Repare Therapeutics Inc. (NASDAQ:RPTX) by 1.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,916,089 shares of the company’s stock after selling 26,466 shares during the quarter. Redmile Group LLC owned about 4.51% of Repare Therapeutics worth $2,510,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Vontobel Holding Ltd. raised its position in Repare Therapeutics by 45.8% in the 4th quarter. Vontobel Holding Ltd. now owns 35,000 shares of the company’s stock worth $46,000 after purchasing an additional 11,000 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in Repare Therapeutics by 204.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 34,423 shares of the company’s stock valued at $45,000 after buying an additional 23,127 shares during the period. Lynx1 Capital Management LP bought a new position in Repare Therapeutics in the fourth quarter valued at approximately $104,000. JPMorgan Chase & Co. lifted its stake in shares of Repare Therapeutics by 2,144,950.0% in the 4th quarter. JPMorgan Chase & Co. now owns 85,802 shares of the company’s stock valued at $112,000 after purchasing an additional 85,798 shares during the period. Finally, Blue Owl Capital Holdings LP grew its position in shares of Repare Therapeutics by 2.1% during the 4th quarter. Blue Owl Capital Holdings LP now owns 3,443,659 shares of the company’s stock worth $4,511,000 after buying an additional 71,160 shares during the period. 85.09% of the stock is currently owned by institutional investors and hedge funds.

Repare Therapeutics Price Performance

RPTX opened at $1.31 on Thursday. The business has a fifty day simple moving average of $1.16 and a 200 day simple moving average of $1.71. Repare Therapeutics Inc. has a 1 year low of $0.89 and a 1 year high of $4.29. The company has a market capitalization of $55.97 million, a PE ratio of -0.65 and a beta of 0.85.

Repare Therapeutics (NASDAQ:RPTX) last released its earnings results on Monday, March 3rd. The company reported ($0.67) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.10. Repare Therapeutics had a negative return on equity of 40.87% and a negative net margin of 99.76%. Equities analysts anticipate that Repare Therapeutics Inc. will post -2.04 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright decreased their price objective on Repare Therapeutics from $10.00 to $5.00 and set a “buy” rating for the company in a research report on Friday, March 7th.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.